<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01062009</url>
  </required_header>
  <id_info>
    <org_study_id>SPID 0876</org_study_id>
    <nct_id>NCT01062009</nct_id>
  </id_info>
  <brief_title>Safety and Dose Escalation Study of Zinc Supplementation in Critically Ill Children</brief_title>
  <official_title>A Safety and Dose-escalation Study of Zinc Supplementation in Pediatric Critical Illness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCSF Benioff Children’s Hospital Oakland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UCSF Benioff Children’s Hospital Oakland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is 1) to determine whether administration of intravenous zinc to
      critically ill children is safe, and 2) to determine an appropriate dose of zinc
      supplementation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our recently published studies in children with septic shock demonstrated that pediatric
      septic shock is characterized by large scale repression of genes that either directly depend
      on normal zinc homeostasis or directly participate in zinc homeostasis. Functional validation
      studies demonstrated that nonsurvivors of pediatric septic shock have abnormally low serum
      zinc concentrations. A follow-up pilot study in a general population of critically ill
      children demonstrated that the presence of low plasma zinc concentrations is a prevalent
      problem in critically ill children. In addition, low plasma zinc concentrations correlate
      inversely with indices of inflammation and directly with the number of organ failures. These
      preliminary data, coupled with the expected safety of zinc supplementation, provided the
      rationale for a double blinded, prospective, placebo-controlled trial of zinc supplementation
      in critically ill children, with the two primary study endpoints to assess efficacy being
      highly clinically relevant: reduction of the lymphopenia rate and improvement of glucose
      homeostasis. Although the proposal was well-received, the primary concern precluding funding
      of this trial were lack of safety and dosing data for intravenous zinc. We have therefore
      developed a proposal for a Phase I/II study of safety and pharmacokinetics to address these
      concerns. It is anticipated that data generated through this proposal will provide the
      necessary preliminary data to re-submit our application for an interventional efficacy trial
      of zinc supplementation in critically ill children
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Zinc Concentration Over Time</measure>
    <time_frame>7 days</time_frame>
    <description>Plasma Zinc levels were measured daily during the seven day study period in each group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>New Fever</measure>
    <time_frame>7 days</time_frame>
    <description>Because of reports of fever in patients wiht zinc overdoses, we monitored patients for new fever while on supplementation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose Homeostasis</measure>
    <time_frame>7 days</time_frame>
    <description>Patients were assigned a score based on glucose range to take into account the degree of hyperglycemia as well as the need for insulin over the course of the 7 day study period. This score is an ordinal scale ranging from 1 to 5, with a score of 1 indicating no hyperglycemia, and 5 indicating severe hyperglycemia despite insulin administration.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>250 mcg/kg/day supplemental IV zinc sulfate divided every 8 hours for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dose group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500 mcg/kg/day supplemental IV zinc sulfate q8 hours for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>750 mcg/kg/day supplemental IV zinc sulfate q8 hrs for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zinc sulfate</intervention_name>
    <description>Zinc sulfate 200 mcg/ml in Normal Saline</description>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_label>Low dose group</arm_group_label>
    <arm_group_label>Medium dose group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admission to pediatric intensive care unit

          -  Age between 1 month and 10 years

          -  Pediatric Risk of Mortality III score &gt; 5, OR presence of at least 1 new organ failure

          -  Anticipated pediatric intensive care unit length of stay &gt; 3 days

          -  Ability of parent or legal guardian to provide informed consent

        Exclusion Criteria:

          -  Known zinc deficiency

          -  Pre-existing bone marrow failure

          -  New or existing diagnosis of diabetes mellitus

          -  Limitation of care orders in place

          -  New diagnosis of brain injury, encephalopathy

          -  Clinical contraindication for zinc supplementation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalie Z Cvijanovich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF Benioff Children’s Hospital Oakland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Childrens' Hospital &amp; Research Center Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cvijanovich NZ, King JC, Flori HR, Gildengorin G, Wong HR. Zinc homeostasis in pediatric critical illness. Pediatr Crit Care Med. 2009 Jan;10(1):29-34. doi: 10.1097/PCC.0b013e31819371ce.</citation>
    <PMID>19057435</PMID>
  </reference>
  <reference>
    <citation>Wong HR, Shanley TP, Sakthivel B, Cvijanovich N, Lin R, Allen GL, Thomas NJ, Doctor A, Kalyanaraman M, Tofil NM, Penfil S, Monaco M, Tagavilla MA, Odoms K, Dunsmore K, Barnes M, Aronow BJ; Genomics of Pediatric SIRS/Septic Shock Investigators. Genome-level expression profiles in pediatric septic shock indicate a role for altered zinc homeostasis in poor outcome. Physiol Genomics. 2007 Jul 18;30(2):146-55. Epub 2007 Mar 20.</citation>
    <PMID>17374846</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>February 2, 2010</study_first_submitted>
  <study_first_submitted_qc>February 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2010</study_first_posted>
  <results_first_submitted>August 16, 2016</results_first_submitted>
  <results_first_submitted_qc>August 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2019</results_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zinc Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One patient was enrolled but withdrawn by PI due to insufficient intravenous access to obtain study labs</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Control Group</title>
          <description>No intervention</description>
        </group>
        <group group_id="P2">
          <title>Low Dose Group</title>
          <description>250 mcg/kg/day supplemental IV zinc sulfate divided every 8 hours for 7 days
Zinc sulfate: Zinc sulfate 200 mcg/ml in Normal Saline</description>
        </group>
        <group group_id="P3">
          <title>Medium Dose Group</title>
          <description>500 mcg/kg/day supplemental IV zinc sulfate q8 hours for 7 days
Zinc sulfate: Zinc sulfate 200 mcg/ml in Normal Saline</description>
        </group>
        <group group_id="P4">
          <title>High Dose Group</title>
          <description>750 mcg/kg/day supplemental IV zinc sulfate q8 hrs for 7 days
Zinc sulfate: Zinc sulfate 200 mcg/ml in Normal Saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control Group</title>
          <description>No intervention</description>
        </group>
        <group group_id="B2">
          <title>Low Dose Group</title>
          <description>250 mcg/kg/day supplemental IV zinc sulfate divided every 8 hours for 7 days
Zinc sulfate: Zinc sulfate 200 mcg/ml in Normal Saline</description>
        </group>
        <group group_id="B3">
          <title>Medium Dose Group</title>
          <description>500 mcg/kg/day supplemental IV zinc sulfate q8 hours for 7 days
Zinc sulfate: Zinc sulfate 200 mcg/ml in Normal Saline</description>
        </group>
        <group group_id="B4">
          <title>High Dose Group</title>
          <description>750 mcg/kg/day supplemental IV zinc sulfate q8 hrs for 7 days
Zinc sulfate: Zinc sulfate 200 mcg/ml in Normal Saline</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.5" lower_limit="0.6" upper_limit="4.8"/>
                    <measurement group_id="B2" value="1.8" lower_limit="0.8" upper_limit="2.8"/>
                    <measurement group_id="B3" value="5.3" lower_limit="1.9" upper_limit="6.4"/>
                    <measurement group_id="B4" value="2.6" lower_limit="0.8" upper_limit="5.2"/>
                    <measurement group_id="B5" value="1.9" lower_limit="0.65" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pediatric Risk of Mortality (PRISM) III</title>
          <description>PRISM is Pediatric Risk of Mortality score The PRISM score has 17 physiologic variables subdivided into 26 ranges. The score for each variable is summed to determine the PRISM score. The minimum score (lowest risk of mortality) is 0 and the maximum score is 70.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12" lower_limit="5" upper_limit="17"/>
                    <measurement group_id="B2" value="8" lower_limit="3" upper_limit="16"/>
                    <measurement group_id="B3" value="12" lower_limit="6" upper_limit="19"/>
                    <measurement group_id="B4" value="9" lower_limit="7" upper_limit="10"/>
                    <measurement group_id="B5" value="9" lower_limit="5" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pediatric Index of Mortality (PIM)</title>
          <description>PIM, or pediatric index of mortality, is a mortality prediction model for children in intensive care. It inputs seven variables and produces a calculated percentage mortality risk ranging from 0-100%</description>
          <units>percentage mortality risk</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.4" lower_limit="1.6" upper_limit="17.1"/>
                    <measurement group_id="B2" value="6.0" lower_limit="4.2" upper_limit="7.2"/>
                    <measurement group_id="B3" value="7.0" lower_limit="4.0" upper_limit="23.0"/>
                    <measurement group_id="B4" value="5.2" lower_limit="2.8" upper_limit="7.8"/>
                    <measurement group_id="B5" value="5.9" lower_limit="4" upper_limit="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pediatric Logistic Organ Dysfunction (PELOD )</title>
          <description>The PeLOD (Pediatric Logistic Organ Dysfunction) score is a measure of multiple organ dysfunction that sums values for 6 organ systems (cardiovascular, respiratory, renal, hepatic, hematologic, and neurologic) to give a number between 0 and 71. The higher the number the worse the organ dysfunction and the greater the risk of mortality.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11" lower_limit="4" upper_limit="11"/>
                    <measurement group_id="B2" value="11" lower_limit="4" upper_limit="19"/>
                    <measurement group_id="B3" value="20" lower_limit="13" upper_limit="21"/>
                    <measurement group_id="B4" value="21" lower_limit="14" upper_limit="21"/>
                    <measurement group_id="B5" value="11" lower_limit="2" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of patients with &gt;= 2 organs failed</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma Zinc Concentration Over Time</title>
        <description>Plasma Zinc levels were measured daily during the seven day study period in each group.</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>No intervention</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Group</title>
            <description>250 mcg/kg/day supplemental IV zinc sulfate divided every 8 hours for 7 days
Zinc sulfate: Zinc sulfate 200 mcg/ml in Normal Saline</description>
          </group>
          <group group_id="O3">
            <title>Medium Dose Group</title>
            <description>500 mcg/kg/day supplemental IV zinc sulfate q8 hours for 7 days
Zinc sulfate: Zinc sulfate 200 mcg/ml in Normal Saline</description>
          </group>
          <group group_id="O4">
            <title>High Dose Group</title>
            <description>750 mcg/kg/day supplemental IV zinc sulfate q8 hrs for 7 days
Zinc sulfate: Zinc sulfate 200 mcg/ml in Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Zinc Concentration Over Time</title>
          <description>Plasma Zinc levels were measured daily during the seven day study period in each group.</description>
          <units>mcg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.2" spread="14.8"/>
                    <measurement group_id="O2" value="36.4" spread="8.8"/>
                    <measurement group_id="O3" value="37.7" spread="25.2"/>
                    <measurement group_id="O4" value="43.4" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.0" spread="10.1"/>
                    <measurement group_id="O2" value="42.1" spread="15.4"/>
                    <measurement group_id="O3" value="46.3" spread="29.1"/>
                    <measurement group_id="O4" value="71.5" spread="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.3" spread="10.7"/>
                    <measurement group_id="O2" value="47.4" spread="17.8"/>
                    <measurement group_id="O3" value="52.3" spread="10.9"/>
                    <measurement group_id="O4" value="68.2" spread="33.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.5" spread="4.3"/>
                    <measurement group_id="O2" value="54.4" spread="17.6"/>
                    <measurement group_id="O3" value="63.3" spread="18.9"/>
                    <measurement group_id="O4" value="101.9" spread="33.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.3" spread="5.1"/>
                    <measurement group_id="O2" value="58.9" spread="12.9"/>
                    <measurement group_id="O3" value="66.8" spread="20.0"/>
                    <measurement group_id="O4" value="71.0" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.8" spread="7.3"/>
                    <measurement group_id="O2" value="62.6" spread="15.7"/>
                    <measurement group_id="O3" value="66.0" spread="16.8"/>
                    <measurement group_id="O4" value="114.0" spread="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.7" spread="4.9"/>
                    <measurement group_id="O2" value="67.1" spread="12.2"/>
                    <measurement group_id="O3" value="67.6" spread="10.8"/>
                    <measurement group_id="O4" value="93.3" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>New Fever</title>
        <description>Because of reports of fever in patients wiht zinc overdoses, we monitored patients for new fever while on supplementation</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>No intervention</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Group</title>
            <description>250 mcg/kg/day supplemental IV zinc sulfate divided every 8 hours for 7 days
Zinc sulfate: Zinc sulfate 200 mcg/ml in Normal Saline</description>
          </group>
          <group group_id="O3">
            <title>Medium Dose Group</title>
            <description>500 mcg/kg/day supplemental IV zinc sulfate q8 hours for 7 days
Zinc sulfate: Zinc sulfate 200 mcg/ml in Normal Saline</description>
          </group>
          <group group_id="O4">
            <title>High Dose Group</title>
            <description>750 mcg/kg/day supplemental IV zinc sulfate q8 hrs for 7 days
Zinc sulfate: Zinc sulfate 200 mcg/ml in Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>New Fever</title>
          <description>Because of reports of fever in patients wiht zinc overdoses, we monitored patients for new fever while on supplementation</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Chi square analysis comparing number of participants with new fever in each group</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Homeostasis</title>
        <description>Patients were assigned a score based on glucose range to take into account the degree of hyperglycemia as well as the need for insulin over the course of the 7 day study period. This score is an ordinal scale ranging from 1 to 5, with a score of 1 indicating no hyperglycemia, and 5 indicating severe hyperglycemia despite insulin administration.</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>No intervention</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Group</title>
            <description>250 mcg/kg/day supplemental IV zinc sulfate divided every 8 hours for 7 days
Zinc sulfate: Zinc sulfate 200 mcg/ml in Normal Saline</description>
          </group>
          <group group_id="O3">
            <title>Medium Dose Group</title>
            <description>500 mcg/kg/day supplemental IV zinc sulfate q8 hours for 7 days
Zinc sulfate: Zinc sulfate 200 mcg/ml in Normal Saline</description>
          </group>
          <group group_id="O4">
            <title>High Dose Group</title>
            <description>750 mcg/kg/day supplemental IV zinc sulfate q8 hrs for 7 days
Zinc sulfate: Zinc sulfate 200 mcg/ml in Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Homeostasis</title>
          <description>Patients were assigned a score based on glucose range to take into account the degree of hyperglycemia as well as the need for insulin over the course of the 7 day study period. This score is an ordinal scale ranging from 1 to 5, with a score of 1 indicating no hyperglycemia, and 5 indicating severe hyperglycemia despite insulin administration.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3.25" upper_limit="4"/>
                    <measurement group_id="O2" value="3.5" lower_limit="3" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="2.5" upper_limit="4"/>
                    <measurement group_id="O4" value="2.5" lower_limit="2" upper_limit="3.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="2.25" upper_limit="4"/>
                    <measurement group_id="O2" value="3.5" lower_limit="2.25" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="2.5" lower_limit="2" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="2.25" upper_limit="4"/>
                    <measurement group_id="O2" value="3.5" lower_limit="2.25" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="3.25" upper_limit="4"/>
                    <measurement group_id="O4" value="2" lower_limit="2" upper_limit="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="3"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="2" lower_limit="2" upper_limit="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="3"/>
                    <measurement group_id="O2" value="4" lower_limit="3.25" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="3.25" upper_limit="4"/>
                    <measurement group_id="O4" value="2" lower_limit="2" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O2" value="3.5" lower_limit="2.25" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="2.5" upper_limit="4"/>
                    <measurement group_id="O4" value="3" lower_limit="3" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2.5" upper_limit="4"/>
                    <measurement group_id="O2" value="2.5" lower_limit="2" upper_limit="3.75"/>
                    <measurement group_id="O3" value="3" lower_limit="3" upper_limit="3"/>
                    <measurement group_id="O4" value="2" lower_limit="1.75" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control Group</title>
          <description>No intervention</description>
        </group>
        <group group_id="E2">
          <title>Low Dose Group</title>
          <description>250 mcg/kg/day supplemental IV zinc sulfate divided every 8 hours for 7 days
Zinc sulfate: Zinc sulfate 200 mcg/ml in Normal Saline</description>
        </group>
        <group group_id="E3">
          <title>Medium Dose Group</title>
          <description>500 mcg/kg/day supplemental IV zinc sulfate q8 hours for 7 days
Zinc sulfate: Zinc sulfate 200 mcg/ml in Normal Saline</description>
        </group>
        <group group_id="E4">
          <title>High Dose Group</title>
          <description>750 mcg/kg/day supplemental IV zinc sulfate q8 hrs for 7 days
Zinc sulfate: Zinc sulfate 200 mcg/ml in Normal Saline</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Refractory hypoxemia</sub_title>
                <description>One patient developed refractory hypoxemia and had to be cannulated for extracorporeal membrane oxygenation on study day 6. He recovered and survived</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size in each group, with multiple comparisons. The study population was varied in age and diagnosis. Plasma zinc does not reflect total body zinc status, therefore a patient with low plasma Zn may not have true zinc deficiency.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Natalie Cvijanovich, MD</name_or_title>
      <organization>UCSF Benioff Childrens Hospital Oakland</organization>
      <phone>510-428-3784</phone>
      <email>NCvijanovich@mail.cho.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

